Document is current
Any future updates will be listed below
-
Authors
He, Meng Xiao
Cuoco, Michael S.
Crowdis, Jett
Bosma-Moody, Alice
Zhang, Zhenwei
Bi, Kevin
Kanodia, Abhay
Su, Mei-Ju
Ku, Sheng-Yu https://orcid.org/0000-0003-4715-1888
Garcia, Maria Mica
Sweet, Amalia R.
Rodman, Christopher
DelloStritto, Laura https://orcid.org/0000-0003-0295-0010
Silver, Rebecca
Steinharter, John
Shah, Parin
Izar, Benjamin https://orcid.org/0000-0003-2379-6702
Walk, Nathan C.
Burke, Kelly P. https://orcid.org/0000-0003-2187-0147
Bakouny, Ziad https://orcid.org/0000-0003-1906-5704
Tewari, Alok K. https://orcid.org/0000-0003-2617-7499
Liu, David
Camp, Sabrina Y.
Vokes, Natalie I. https://orcid.org/0000-0002-3766-5335
Salari, Keyan
Park, Jihye
Vigneau, Sébastien
Fong, Lawrence https://orcid.org/0000-0002-6428-428X
Russo, Joshua W. https://orcid.org/0000-0001-5481-0090
Yuan, Xin
Balk, Steven P. https://orcid.org/0000-0002-4546-7371
Beltran, Himisha https://orcid.org/0000-0003-3259-2226
Rozenblatt-Rosen, Orit https://orcid.org/0000-0001-6313-3570
Regev, Aviv https://orcid.org/0000-0003-3293-3158
Rotem, Asaf
Taplin, Mary-Ellen
Van Allen, Eliezer M. https://orcid.org/0000-0002-0201-4444
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01 CA227388, U01 CA233100, T32 GM008313, K08 CA222663, T32 CA009172, T32 CA009172, K08 CA234458, U01 CA233100, R01 CA223484, R37 CA241486-01A1)
Ambrose Monell Foundation
V Foundation for Cancer Research
Mark Foundation
National Science Foundation (GRFP DGE1144152)
Prostate Cancer Foundation (18YOUN10, 18YOUN24, 16CHAS03)
Burroughs Wellcome Fund
Conquer Cancer Foundation
Society for Immunotherapy of Cancer
Damon Runyon Cancer Research Foundation
Dana-Farber Cancer Institute (Pan Mass Challenge Funds (Team Fat Boys / Slim Sisters))
- License Information
-
More Information
Article History
Received: 20 June 2020
Accepted: 13 January 2021
First Online: 4 March 2021
Competing interests
: M.X.H. has been a consultant to Amplify Medicines and Ikena Oncology. Z.B. reports research support from Bristol-Meyers Squibb (BMS) and Genentech/imCORE unrelated to the current study. B.I. is a consultant for Merck and Volastra Therapeutics. D.L. reports funding by a postdoctoral fellowship from the Society for Immunotherapy of Cancer, which is funded in part by an educational grant from BMS. BMS has had no input into the conception, conduct or reporting of the submitted work. N.I.V. has served on an advisory board for Sanofi/Genzyme and is supported by a grant from the Society of Immunotherapy of Cancer that is funded in part by Genentech. L.F. reports receiving commercial research grants from AbbVie, Bavarian Nordic, BMS, Dendreon, Janssen, Merck and Roche/Genentech. S.P.B. served as an advisor for Sanofi. H.B. reports advisory/consulting from Janssen, Amgen, Astra Zeneca, Pfizer, Astellas, Sanofi Genzyme and research funding from Janssen, AbbVie Stemcentryx, Eli Lilly, Millenium and Astellas. A. Regev is a founder and equity holder of Celsius Therapeutics, an equity holder in Immunitas Therapeutics and, until 31 August 2020, was a SAB member of Syros Pharmaceuticals, Neogene Therapeutics, Asimov and Thermo Fisher Scientific; from 1 August 2020, A. Regev is an employee of Genentech. A. Rotem is an employee of Astra Zeneca and an equity holder in NucleAI and Celsius Therapeutics. M.-E.T. reports advisory relationships with Celgene, Janssen, GSK/Parexel, Bayer, Astra Zeneca, Riovant, AbbVie, Arcus, Astellas, Pfizer, Constellation, Summus Global, MH Life Sciences/Intellisphere, Targeted Oncology and Aptitude Health. E.M.V.A. reports advisory relationships and consulting with Tango Therapeutics, Genome Medical, Invitae, Illumina, Enara Bio, Manifold Bio and Janssen; research support from Novartis and BMS; equity in Tango Therapeutics, Genome Medical, Syapse, Manifold Bio and Enara Bio; and travel reimbursement from Roche and Genentech, outside the submitted work.
